Proliferation rates in human malignant melanoma: Relationship to clinicopathological features and outcome

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 271-277

  Laing, J Hamish E ^a,b   Wilson, George D ^a   Martindale, Christine A ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Bromodeoxyuridine; Cell proliferation; Flow cytometry; Malignant melanoma; Prognosis

Indexed keywords

BROXURIDINE;

ADULT; ARTICLE; CANCER GROWTH; CELL CYCLE S PHASE; CELL KINETICS; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; MALE; MELANOMA; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PARAMETER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SKIN CANCER; SKINFOLD;

AGED; BROMODEOXYURIDINE; CELL DIVISION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; PROGNOSIS; S PHASE; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038516803     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00008     Document Type: Article

References (28)

1. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8(6):400-414.
2. Slingluff CL Jr, Seigler HF. 'Thin' malignant melanoma: risk factors and clinical management. Ann Plast Surg 1992; 28(1):89-94.
3. Blessing K, McLaren KM, McLean A, Davidson P. Thick malignant melanomas (greater than 3 mm Breslow) with good clinical outcome: a histological study and survival analysis. Histopathology 1991; 18(2):143-148.
4. Silvestrini R, Daidone MG. Review of proliferative variables and their predictive value. Recent Results Cancer Res 1993; 127:71-76.
5. Wilson GD, McNally NJ, Dische S, Saunders MI, Des Rochers C, Lewis AA, Bennett MH. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1988; 58(4):423-431.
6. Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol 2000; 26(4):405-417.
7. Laing JH, Rew DA, Wilson GD. Cell kinetics of human solid tumours. BJR Suppl 1992; 24:163-167.
8. Costa A, Silvestrini R, Grignolio E, Clemente C, Attili A, Testori A. Cell kinetics as a prognostic toot in patients with metastatic malignant melanoma of the skin. Cancer 1987; 60(11):2797-2800.
9. Bartkowiak D, Schumann J, Otto FJ, Lippold A, Drepper H. DNA flow cytometry in the prognosis of primary malignant melanoma. Oncology 1991; 48(1):39-43.
10. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989; 11(4):301-307.
11. Rieger E, Hofmann-Wellenhof R, Soyer HP, Kofler R, Cerroni L, Smolle J, Kerl H. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol 1993; 20(3):229-236.
12. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 2001; 195(5):530-536.
13. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000; 6(9):3614-3620.
14. Tran TA, Ross JS, Carlson JA, Mihm MC Jr. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 1998; 29(10):1085-1090.
15. Karlsson M, Boeryd B, Carstensen J, Kagedal B, Bratel AT, Wingren S. DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Br J Cancer 1993; 67(1):134-138.
16. Muhonen T, Pyrhonen S, Laasonen A, Wasenius VM, Asko-Seljavaara S, Franssila K, Kangas L. Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma. Br J Cancer 1992; 66(3):528-532.
17. Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, Wick MR. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol 2000; 13(3):217-222.
18. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p66-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56(23):5475-5483.
19. Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg 1998; 85(1):46-51.
20. Bales ES, Dietrich C, Bandyopadhyay D, Schwahn DJ, Xu W, Didenko V, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113(6):1039-1046.
21. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74(3):255-259.
22. Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol 1990; 95(3):320-324.
23. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol 2001; 44(2):188-192.
24. Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jeronimo C. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000; 43(6):991-1000.
25. Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Franssila K, et al. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma. Oncology 1999; 57(3):242-252.
26. Costa A, Silvestrini R, Mezzanotte G, Vaglini M, Grignolio E, Clemente C, Cascinelli N. Cell kinetics: an independent prognostic variable in stage II melanoma of the skin. Br J Cancer 1990; 62(5):826-829.
27. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995; 105(1):22-26.
28. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193(3):377-388.